Evermil (Everolimus) 10 mg
Evermil 10 mg is a targeted cancer therapy containing Everolimus, an mTOR inhibitor.
Manufacturer: Glenmark Pharmaceuticals (India). A premium generic equivalent of Afinitor.
Mechanism: Stopping the "Engine"
Everolimus binds to a protein called mTOR within cancer cells. mTOR acts like a master switch for cell growth. By blocking it, Evermil stops cancer cells from dividing and cuts off their blood supply (anti-angiogenesis).
✅ Key Benefit: Effective in overcoming resistance to hormonal therapies in breast cancer and other targeted therapies in kidney cancer.
Indicated for the treatment of:
- Advanced Renal Cell Carcinoma (RCC): After failure of sunitinib or sorafenib.
- Breast Cancer: HR-positive, HER2-negative advanced breast cancer (in combination with Exemestane).
- Neuroendocrine Tumors (NET): Of pancreatic, gastrointestinal, or lung origin.
Strength: 10 mg tablet.
Standard Dosage: 10 mg once daily.
⚠️ Administration Instructions:
- Take at the same time every day.
- Take consistently either with food or without food (do not alternate).
- Swallow whole with a glass of water. Do not crush.
- Severe hepatic impairment (requires dose reduction).
- Pregnancy and breastfeeding.
- Known hypersensitivity to rapamycin derivatives.
- Uncontrolled active infections.
Most Common: Oral Stomatitis (Mouth Ulcers).
Very common within the first 8 weeks. Tip: Use alcohol-free mouthwash or salt/baking soda rinses daily to prevent severity.
Other risks:
- Non-infectious Pneumonitis: Watch for new cough or shortness of breath.
- Rash, fatigue, and diarrhea.
- Increased risk of infections (immunosuppression).
What Customers Say
No reviews yet
Your review can be the first!